Skip to main content
SpringerLink
Log in

New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis

  • Management of Heart Failure (T Meyer, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

 Abstract

Systemic amyloidoses are rare and proteiform diseases, caused by extracellular accumulation of insoluble misfolded fibrillar proteins. Prognosis is dictated by cardiac involvement, which is especially frequent in light chain (AL) and in transthyretin variants (ATTR, both mutated, (ATTRm), and wild-type, (ATTRwt)). Recently, ATTRwt has emerged as a potentially relevant cause of a heart failure with preserved ejection fraction (HFpEF). Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction. Independent of the aetiology, cardiac amyloidosis is associated with left ventricular concentric “hypertrophy” (i.e. increased wall thickness), preserved (or mildly depressed) ejection fraction, reduced midwall fractional shortening and global longitudinal function, as well as evident diastolic dysfunction, up to an overly restrictive pattern of the left ventricular filling. Cardiac biomarkers such as troponins and natriuretic peptides are very robust and widely accepted diagnostic as well as prognostic tools. Owing to its dismal prognosis, accurate and early diagnosis is mandatory and potentially life-saving. Although pathogenesis is still not completely understood, direct cardiomyocyte toxicity of the amyloidogenic precursor proteins and/or oligomer aggregates adds on tissue architecture disruption caused by amyloid deposition. The clarification of mechanisms of cardiac damage is offering new potential therapeutic targets, and several treatment options with a relevant impact on prognosis are now available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96.

    Article  CAS  PubMed  Google Scholar 

  2. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75–84.

    Article  CAS  PubMed  Google Scholar 

  3. • Lavatelli F, Imperlini E, Orru S, et al. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB J. 2015;29(11):4614–28. The paper reports recent advances in the current understanding of mechanisms of amyloid-induced cell dysfunction.

    Article  CAS  PubMed  Google Scholar 

  4. Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104(14):1594–7.

    CAS  PubMed  Google Scholar 

  5. Mishra S, Guan J, Plovie E, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013;305(1):H95–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010;107(9):4188–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008–10.

    Article  CAS  PubMed  Google Scholar 

  8. • Guan J, Mishra S, Qiu Y, et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med. 2014;6(11):1493–507. The paper reports recent advances in the current understanding of mechanisms of amyloid-induced cell dysfunction.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Guan J, Mishra S, Shi J, et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol. 2013;108(5):378.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2005;12(1):1–4.

    Article  CAS  PubMed  Google Scholar 

  11. Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid. 2007;14(3):179–83.

    Article  CAS  PubMed  Google Scholar 

  12. Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343–50.

    Article  CAS  PubMed  Google Scholar 

  13. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010;17(3-4):101–4.

    Article  CAS  PubMed  Google Scholar 

  14. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–12.

    Article  CAS  PubMed  Google Scholar 

  15. •• Connors LH, Sam F, Skinner M, et al. Heart failure due to age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2015. Excellent review on cardiac wild-type transthyretin amyloidosis.

  16. •• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520–8. Characterization of the disease profile in cardiac hereditary transthyretin amyloidosis.

    Article  CAS  PubMed  Google Scholar 

  17. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011;124(9):1079–85.

    Article  PubMed  Google Scholar 

  18. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520–30.

    Article  CAS  PubMed  Google Scholar 

  19. Perfetti V, Palladini G, Casarini S, et al. The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012;119(1):144–50.

    Article  CAS  PubMed  Google Scholar 

  20. Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol. 2016;263(5):916–24.

    Article  CAS  PubMed  Google Scholar 

  21. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. •• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124–30. Excellent update in light chain amyloidosis treatment.

    Article  CAS  PubMed  Google Scholar 

  23. Connors LH, Richardson AM, Theberge R, Costello CE. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid. 2000;7(1):54–69.

    Article  CAS  PubMed  Google Scholar 

  24. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786–91.

    Article  CAS  PubMed  Google Scholar 

  25. • Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(1):21–9. Cardiac V122I transthyretin amyloidosis in elderly black Americans.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466–73.

    Article  CAS  PubMed  Google Scholar 

  27. Jacobson DR, Pastore R, Pool S, et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet. 1996;98(2):236–8.

    Article  CAS  PubMed  Google Scholar 

  28. Buck FS, Koss MN, Sherrod AE, Wu A, Takahashi M. Ethnic distribution of amyloidosis: an autopsy study. Mod Pathol : Off J U S Can Acad Pathol Inc. 1989;2(4):372–7.

    CAS  Google Scholar 

  29. Westermark P, Sletten K, Johansson B, Cornwell 3rd GG. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990;87(7):2843–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165(12):1425–9.

    Article  PubMed  Google Scholar 

  31. Cornwell 3rd GG, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75(4):618–23.

    Article  PubMed  Google Scholar 

  32. Tanskanen M, Kiuru-Enari S, Tienari P, et al. Senile systemic amyloidosis, cerebral amyloid angiopathy, and dementia in a very old Finnish population. Amyloid. 2006;13(3):164–9.

    Article  PubMed  Google Scholar 

  33. •• Gillmore JD, Maurer MS, Falk RH, et al: Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12. Key paper illustrating the current diagnostic workup in transthyretin amyloidosis.

  34. Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016.

  35. Dorbala S, Vangala D, Bruyere Jr J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2(4):358–67.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Bernardi L, Passino C, Porta C, Anesi E, Palladini G, Merlini G. Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? Heart. 2002;88(6):615–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Perlini S, Salinaro F, Musca F, et al. Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. J Hypertens. 2014;32(5):1121–31. discussion 1131.

    Article  CAS  PubMed  Google Scholar 

  38. Ghio S, Perlini S, Palladini G, et al. Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail. 2007;9(8):808–13.

    Article  PubMed  Google Scholar 

  39. Buss SJ, Emami M, Mereles D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012;60(12):1067–76.

    Article  PubMed  Google Scholar 

  40. Quarta CC, Kruger JL, Falk RH. Cardiac amyloidosis. Circulation. 2012;126(12):e178–82.

    Article  PubMed  Google Scholar 

  41. Cappelli F, Porciani MC, Bergesio F, et al. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging. 2012;13(5):416–22.

    Article  PubMed  Google Scholar 

  42. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440–5.

    Article  CAS  PubMed  Google Scholar 

  43. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426–30.

    Article  CAS  PubMed  Google Scholar 

  44. Palladini G, Barassi A, Perlini S, et al. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid. 2011;18(4):216–21.

    Article  CAS  PubMed  Google Scholar 

  45. Kristen AV, Rosenberg M, Lindenmaier D, et al. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid. 2014:1-9.

  46. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.

    Article  CAS  PubMed  Google Scholar 

  47. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104(6):1881–7.

    Article  CAS  PubMed  Google Scholar 

  48. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–7.

    Article  CAS  PubMed  Google Scholar 

  50. Perlini S, Obici L, dell’Acqua R, et al: Differences in NT-proBNP release in patients with cardiac m-ATTR depend on the specific transthyretin mutation. Book of Abstracts, XIV International Symposium on Amyloidosis (27 April – 1 May 2014) - Amyloid: Insoluble but solvable 2014.

  51. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.

    Article  CAS  PubMed  Google Scholar 

  52. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535–7.

    Article  PubMed  Google Scholar 

  53. Mussinelli R, Salinaro F, Alogna A, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013;18(3):271–80.

    Article  PubMed  Google Scholar 

  54. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477–81.

    Article  PubMed  Google Scholar 

  55. Boldrini M, Salinaro F, Mussinelli R, et al. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac Al amyloidosis. Ann Noninvasive Electrocardiol. 2013;18(4):327–35.

    Article  PubMed  Google Scholar 

  56. Perlini S, Salinaro F, Cappelli F, et al. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol. 2013;167(5):2156–61.

    Article  PubMed  Google Scholar 

  57. Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J. 2002;23(2):157–61.

    Article  CAS  PubMed  Google Scholar 

  58. Dubrey SW, Bilazarian S, LaValley M, Reisinger J, Skinner M, Falk RH. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J. 1997;134(6):994–1001.

    Article  CAS  PubMed  Google Scholar 

  59. Palladini G, Perlini S, Merlini G: Imaging of systemic amyloidosis. In: Amyloidosis: Diagnosis and Treatment. Edited by Gertz MR, SV (eds): Humana Press; 2010: 15–32.

  60. •• Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7(3):552–62. Review of imaging in cardiac amyloidosis.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.

    Article  PubMed  Google Scholar 

  62. Dungu J, Whelan CJ, Gibbs SD, et al. Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis. J Cardiovasc Magn Reson. 2012;14 Suppl 1:O87.

    Article  PubMed Central  Google Scholar 

  63. Ruberg FL, Appelbaum E, Davidoff R, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol. 2009;103(4):544–9.

    Article  PubMed  Google Scholar 

  64. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51(10):1022–30.

    Article  PubMed  Google Scholar 

  65. Kwong RY, Heydari B, Abbasi S, et al. Characterization of cardiac amyloidosis by atrial late gadolinium enhancement using contrast-enhanced cardiac magnetic resonance imaging and correlation with left atrial conduit and contractile function. Am J Cardiol. 2015;116(4):622–9.

    Article  PubMed  PubMed Central  Google Scholar 

  66. •• Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–9. Role of magnetic resonance imaging in cardiac amyloidosis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–84.

    Article  PubMed  Google Scholar 

  68. Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–97.

    Article  PubMed  Google Scholar 

  69. Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157–65.

    Article  PubMed  Google Scholar 

  70. Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–9.

    Article  PubMed  Google Scholar 

  71. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.

    CAS  PubMed  Google Scholar 

  72. • Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015;36(18):1098–105. Assessment of the death modalities in cardiac AL amyloidosis.

    Article  PubMed  Google Scholar 

  73. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–57.

    Article  CAS  PubMed  Google Scholar 

  74. Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015;278(2):126–44.

    Article  CAS  PubMed  Google Scholar 

  75. Modesto KM, Dispenzieri A, Cauduro SA, et al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J. 2005;26(2):173–9.

    Article  PubMed  Google Scholar 

  76. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119(18):2490–7.

    Article  CAS  PubMed  Google Scholar 

  77. • Gertz MA, Lacy MQ, Dispenzieri A, et al: Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. Cancer. 2016;122(14):2197–2205. Current treatment options in AL amyloidosis.

  78. •• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2015;387(10038):2641–54. A comprehensive up-to-date review.

  79. Stevens JM, Patton WN, Heaton DC, et al. Autologous PBSCT in patients with cardiac amyloidosis. Bone Marrow Transplant. 2000;26(5):588–9.

    Article  CAS  PubMed  Google Scholar 

  80. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276–82.

    Article  CAS  PubMed  Google Scholar 

  81. Reece DE, Hegenbart U, Sanchorawala V, et al: Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014.

  82. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787–8.

    Article  CAS  PubMed  Google Scholar 

  83. Palladini G, Milani P, Foli A, et al: Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia. 2014.

  84. Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99(4):743–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Venner CP, Lane T, Foard D, et al: Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival. Blood. 2012.

  86. Sanchorawala V, Finn KT, Fennessey S, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood. 2010;116(11):1990–1.

    Article  CAS  PubMed  Google Scholar 

  87. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457–64.

    Article  CAS  PubMed  Google Scholar 

  88. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936–8.

    Article  CAS  PubMed  Google Scholar 

  89. Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009;88(4):347–50.

    Article  CAS  PubMed  Google Scholar 

  90. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031–7.

    Article  CAS  PubMed  Google Scholar 

  91. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341(8853):1113–6.

    Article  CAS  PubMed  Google Scholar 

  92. • Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–67. Diflunisal in transthyretin amyloidosis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. • Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–14. Tafamidis in transthyretin amyloidosis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. • Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–29. RNAi therapy in transthyretin amyloidosis.

    Article  CAS  PubMed  Google Scholar 

  95. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19 Suppl 1:34–6.

    Article  CAS  PubMed  Google Scholar 

  96. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Dey BR, Chung SS, Spitzer TR, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010;90(8):905–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Gibbs SD, Sattianayagam PT, Hawkins PN, Gillmore JD. Cardiac transplantation should be considered in selected patients with either AL or hereditary forms of amyloidosis: the UK National Amyloidosis Centre experience. Intern Med J. 2009;39(11):786–7. author reply 787-788.

    Article  CAS  PubMed  Google Scholar 

  99. Roig E, Almenar L, Gonzalez-Vilchez F, et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant. 2009;9(6):1414–9.

    Article  CAS  PubMed  Google Scholar 

  100. Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation. 2007;83(5):539–45.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Medica II, Department of Internal Medicine, University of Pavia, P. le Golgi 19, 27100, Pavia, Italy

    Stefano Perlini, Roberta Mussinelli & Francesco Salinaro

  2. Amyloidosis Research and Treatment Center, Fondazione Policlinico IRCCS San Matteo, University of Pavia, P. le Golgi 19, 27100, Pavia, Italy

    Stefano Perlini

  3. Experimental Medicine PhD Program, University of Pavia, Pavia, Italy

    Francesco Salinaro

Authors
  1. Stefano Perlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberta Mussinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Salinaro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Perlini.

Ethics declarations

Conflict of Interest

Stefano Perlini, Roberta Mussinelli, and Francesco Salinaro declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Management of Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perlini, S., Mussinelli, R. & Salinaro, F. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis. Curr Heart Fail Rep 13, 267–272 (2016). https://doi.org/10.1007/s11897-016-0311-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-016-0311-y

Keywords

Search

Navigation